Rob is operating partner at BGV since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. Currently he serves on the board of SurgVision and Mellon Medical.
Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles.Rob moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences. Rob was subsequently CEO of Dezima Pharma , which was sold to Amgen in October 2015.
Rob holds a MSc in pharmacy from the University of Groningen.
Byk Gulden, Medtronic, Crucell, bmeye